Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori.

BACKGROUND: Triple therapy including a proton pump inhibitor, clarithromycin, and amoxicillin (PPI-CA) is the first-choice treatment used for H. pylori eradication. The efficacy of this treatment is declining of late, and alternative therapies are currently under evaluation. OBJECTIVES: To evaluate...

Descripción completa

Detalles Bibliográficos
Publicado en:Spanish Journal of Gastroenterology / Revista Española de Enfermedades Digestivas Vol. 101; no. 6; pp. 395 - 403
Autores principales: Castro-Fernández M, Lamas E, Pérez-Pastor A, Pabón M, Aparcero R, Vargas-Romero J, Larraona JL, Romero-Gómez M
Formato: research tables/charts Journal Article
Publicado: Aran Ediciones S.A. 2009 Jun
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105424075&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105424075
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11300108
        YU3
      jtl: Spanish Journal of Gastroenterology / Revista Española de Enfermedades Digestivas
      issn: 11300108
      maglogo: N
    pubinfo:
      dt: 2009 Jun
      vid: 101
      iid: 6
      pid: 20394
      pub: Aran Ediciones S.A.
    artinfo:
      ui:
        105424075
        105424075
        2010392957
        NLM19630462
        105424075
      ppf: 395
      ppct: 8
      formats:
      tig:
        atl: Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori.
      aug:
        au:
          Castro-Fernández M
          Lamas E
          Pérez-Pastor A
          Pabón M
          Aparcero R
          Vargas-Romero J
          Larraona JL
          Romero-Gómez M
        affil: Unit for the Clinical Management of Digestive Diseases, Hospital Universitario de Valme, Sevilla, Spain. mcastrof@meditex.es
      sug:
        subj:
          Amoxicillin Administration and Dosage
          Drug Therapy, Combination Methods
          Helicobacter Infections Therapy
          Ofloxacin Administration and Dosage
          Proton Pump Inhibitors Administration and Dosage
          Female
          Gastroenterology Care
          Male
          Spain
          Human
          Female
          Male
      ab: BACKGROUND: Triple therapy including a proton pump inhibitor, clarithromycin, and amoxicillin (PPI-CA) is the first-choice treatment used for H. pylori eradication. The efficacy of this treatment is declining of late, and alternative therapies are currently under evaluation. OBJECTIVES: To evaluate the efficacy, safety and compliance of a triple therapy with a PPI, amoxicillin and levofloxacin (PPI-LA)--replacing clarithromycin--for the eradication of H. pylori. METHODS: The study included 135 patients (65% women), mean age 53 years, with dyspeptic symptoms and H. pylori infection proven by a positive urease rapid test, histological analysis, or C13-urea breath test. Diagnosis: non-investigated dyspepsia 48.9%, functional dyspepsia 36.3%, and ulcerative dyspepsia 14.8%. Treatment was indicated with a proton pump inhibitor at usual doses, amoxicillin 1 g, and levofloxacin 500 mg, administered jointly during breakfast and dinner for 10 days. We studied the performance of this triple therapy and its effects using a questionnaire, and effectiveness by the negativity of the C13-urea breath test after 6-8 weeks after treatment discontinuation. Per protocol, we compared the effectiveness of PPI-LA with a control group of 270 patients treated with PPI-CA for 10 days. RESULTS: 130 patients (96.2%) could complete the treatment and follow-up protocol. Effectiveness (intention to treat) was 71.8% (97/135) and 74.6% (per protocol) (97/130). Sixteen patients (11.8%) had well-tolerated adverse effects, except for 5 subjects (3.7%) who dropped out. PPI-CA was effective (per protocol) in 204 patients out of 270 (75.5%) in the control group. CONCLUSIONS: Triple therapy with a PPI, amoxicillin and levofloxacin for 10 days is a well-tolerated treatment that is easy to comply with; however it has low efficiency - less than 80% - and is not recommended as a first-choice treatment for H. pylori eradication. Similar results were obtained with the classic triple therapy using a PPI, clarithromycin and amoxicillin.
      pubtype: Periodical
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N